HPV (Human Papillomavirus)-associatedNCT06661083
The Effect of Natural Molecules on HPV Infection
A study testing EGCG, FA, HA, B12 in people with HPV (Human Papillomavirus)-associated, run by AGUNCO Obstetrics and Gynecology Centre at 1 site in Italy.
Trial summary
The purpose of the study is to evaluate the effect of the administration of natural molecules in the treatment of HPV infection. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- HPV (Human Papillomavirus)-associated
- What is being tested?
- EGCG, FA, HA, B12
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 106 participants
- Where
- 1 siteItaly
- Study dates
- 1 Aug 2024to 7 Mar 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- HPV DNA test positivity
- over 18 years
Who cannot join
- pregnancy
- breastfeeding
- assumption of other products containing EGCG or green tea
- primary immunodepression or pharmacological induced one
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Counteracting HPV Infection with Natural Molecules
The purpose of the study is to evaluate the effect of the administration of natural molecules in the treatment of HPV infection.
- Conditions
- HPV (Human Papillomavirus)-associated
- Being tested
- EGCG, FA, HA, B12
- Medical subject headings
- Papillomavirus Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EGCG, FA, HA, B12Dietary supplement
EGCG + FA + HA + B12 (1 cps /die)
| Study group | Role | What they receive |
|---|---|---|
| Patients with HPV infection | Experimental | Not described Receives: Dietary Supplement: EGCG, FA, HA, B12 |
What is being measured
The primary outcome is the main question the study is designed to answer.
HPV DNA test negativity
Percentage
Measured: 6 months of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2024
- Study start1 Aug 2024
- Primary completion28 Feb 2025
- Study completion7 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HPV (Human Papillomavirus)-associatedStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 106 participants (actual)
Sponsor and investigators
- Lead sponsor
- AGUNCO Obstetrics and Gynecology Centre
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06661083
- Sponsor's protocol ID
- Epistop_2024
- Status last verified
- Mar 2025
- First submitted
- 23 Oct 2024
- Last updated
- 19 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Counteracting HPV Infection with Natural Molecules
- ClinicalTrials.gov ID
- NCT06661083
- Acronym / sponsor ID
- Epistop_2024
- Conditions
- HPV (Human Papillomavirus)-associated
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 106 participants (actual)
- Lead sponsor
- AGUNCO Obstetrics and Gynecology CentreUniversity, hospital or other
- Study start
- 1 Aug 2024 (actual)
- Primary completion
- 28 Feb 2025 (actual)
- Study completion
- 7 Mar 2025 (actual)
- First posted
- 28 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to evaluate the effect of the administration of natural molecules in the treatment of HPV infection.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with HPV infection | Experimental | Dietary Supplement: EGCG, FA, HA, B12 |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- HPV DNA test positivity
- over 18 years
Key exclusion criteria (4 listed)
- pregnancy
- breastfeeding
- assumption of other products containing EGCG or green tea
- primary immunodepression or pharmacological induced one
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EGCG, FA, HA, B12EGCG + FA + HA + B12 (1 cps /die) | Dietary supplement | Patients with HPV infection |
Primary outcome
HPV DNA test negativity
Time frame: 6 months of treatment
Percentage
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2025.
Related trials for HPV (Human Papillomavirus)-associated
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
RecruitingObservational study
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
Cervical Cancer, Cervical Dysplasia
Not yet recruiting
C2001P-CS3: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV
Human Papillomavirus (HPV), HPV Associated Cancers
RecruitingPhase 2
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Cervical Cancer, Throat Cancer
Not yet recruiting
The Effect of Health Belief Model-Based HPV Infection and Vaccination Education on University Students' Knowledge and Health Beliefs
Health Belief Model, Nursing Students
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EGCG, FA, HA, B12 in people with HPV (Human Papillomavirus)-associated, run by AGUNCO Obstetrics and Gynecology Centre at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HPV DNA test negativity (time frame: 6 months of treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2025.